There are numerous growing evidences of resemblance between carcinomas of the breast and prostate. A total of 48 cases of these two hormone-dependent cancers along with approprlats controls were subjected for status of epidermal growth factor receptors as well as serum lipid profile. Paraffin embedded tissue sections from afonmald tumum were analysed by immunohistochemical stuining for epidermal growth factor receptor (EGF-R), c-erbB-2 oncoprotsin, nslxogen mcapt~ (ER) and Wogestmmne receptor (PgR). Sere from same individuals were studied for serum lipid profile analysis. The study revealed that immunoexpression of all receptor proteins (EGF-R). c-erbB-2 was significantly higher in breast carcinoma. In addition, mean levels of triglyc~Ntdas, total cholesterol, LDL-cholestsrol were found to be significantly elevated while the level of HDL-cholesterol was observed to be lower among patients with breast cancer as compared to matched oonlxols. Further, ER-posilive breast cancar cases have significant~ higher mean level of HDL-cholasterol when compared with ER-negative breast cancer patients. Contrary to this, no alteration in different serum lipid fractions was noticed among the patients with prostate cancer. However, a positive relationship was noticed between immunoexpressions of EGF-R and c-erbB-2 in prostate cancer.
INTRODUCTION
Breast cancer is the second most common malignarcy among Indian women; but, it ranks highest in women population of Mumbai. In developed countries, breast cancer is the commonest female cancer. The epidernioiogical evidences have strongly supported the hypothesis that environmental, hormonal, and genetic factors affect the risk for development of breast cancer (1, 2) . Environmental factors like increased total calories and fat consumption in w~rnen of higher socioeconomic status appear to increase the risk (3) . Similarly, nonvegetarian (non-veg) diets may have some role inthe dev opment of rwmone-relatad cancers (4) . Recer Author for correspondence: Dr. B.K. Sharrna, Deputy Director, at above address Fax : 323 3406 published reports have documented the altered levels of serum lipids in patients with different stages of breast cancer as well as changes in various serum lipid fractions in relation to progression of the cancer (5-7).
Out of all identified risk factors of breast cancer, age at menarche, age at first pregnancy, and age at menopause suggest that endogenous steroid may profoundly ~l'ect initiation, promotion, and prog~ of carcinogenesis (8) . EsUogens are physiological mitogens for mammary cells. During malignant transformation, cells exploit this mitogenic action, whirl1 is involved in progressive accumulation of gefmtJc alterations, such as ~2 amplification, p53 mutation, over.expression of estrogen receptor (ER), etc (9, 10) . Invasive cancers can thereafter become independent from esCrogefls, likely through the acquisition of further genetic changes. Apart from mammary cell growth stimulation, estrogens profoundly influence cell-cell communication and stromal-epithelial interaction, by increasing the secretion of autocrine and paracrine growth factors
(9).
There are interesting similarities between carcinomas of the breast and prostate, aside from epidemiotogical and social factors. Both are mainly adenocarcinomas arising in sexually differentiated organs and bo~ are strongly influenced by sex __-steroi d. " hormones. Since the hormones play a pivotal role in controlling growth and proliferation of prostatic epithelium, it is speculated that the same hormones might be intimately involved in al0normal prostatic growth including carcinogenesis, like pathological process of breast cancer. Further, genetic components are ffmught to involve in pathogenesis in both carcinomas of the breast and prostate. Recent studies on immunoexl~-ess~on of c-erbB-2 oncoproteln in prostate cancer have revealed its prognostic significance as a indicator of poor prognosis (11, 12) . Although, various studies have linked over-expression of epidermal growth factor receptor (EGF-R) with a poor prognosis in breast cancer;, this association however, has not been demonstrated in prostate cancel'.
The age-adjusted incidence rate of male genital tract cancers including prostate cancer are considerably low as per reports of carmer registries of India. Contrary to this, prostate cancer is a leading cancer in United States, which has demonstrated a steady increase in incidence and mortality (13) . Several studies have implicated an association between high fat consumption and prostate cancer risk, similar to breast cancer (14) . ~, food habits have a relation with sex-steroid hormones in pathogenesis of both breast and prostate cancers. Similarly, members of growth factor receptors family, lipid metabolism, various steroid-related factors, etc. have an intimate association with the hormones. Therefore, the present study was aimed to evaluate immunoexpressions of epidermal growth factor receptors (EGF-R, c-erbB-2) and hormonal receptors (ER, PgR) along with serum lipid profile in order to understand their interrelationships in carcinomas of the breast and prostate.
MATERIALS AND METHODS
The study was undertaken in collaboration with All tissue sections (5p.m thick) from cases and controls (benign diseases) were subjected to routine hasmatoxyline and eosin staining for histopat~ogical diagnosis and invnunohistochemical staining for EGF-R, c-erbB-2 oncoprotein, ER and progesterone receptor (PgR). Immunohistochernical staining was performed as described by Ratnakar et al (15) . The murine monocional antibodies directed against the extracellular domain of EGF-R (Sigma, USA) and cerbB-2 protein (Boehringer Mannheim, Gen~any) as well as ER (ER-D5 antigen, ~m, UK) and PgR (Sigma, USA) were used as primary antibodies. The sections were deparaffinized with xylene and toluene, then put through successive alcohol washes, rehydrated and washed in phosphate buffered saline (PBS). The tissue sections ware treated with 6% hydrogen peroxide in methanol to block endogenous peroxidase enzyme activity of the tissue, which were followed by incubation with mouse normal serum. Tissue sec~ons were further inculoated with optimally dilutad primary antibody for I hour at room temperature in humid chamber. After washing them in PBS, the tissue sections were incubated with secondary antibody for I hour, followed by washing in PBSWIth Tween 20 (0.005%). The tissue sections were finally incubated with mouse peroxidase-antiperoxidase (PAP) complex. Immunoreactivity of membrane (EGF-R and c-erbB-2)/nuclear (ER and PgR) antigenswere visualized by sub=,b ~e diaminobenzidine (DAB, 0.1% solution in PBS with 0.05% hydrogen peroxide).
Peripheral venous blood samples were collected after an ovemight fast, from patients before initiation of any systemic treatment and/or radiotherapy. In addition to this, blood samples were also collected from 25 women (mean age: 46.2:1:12.13 years) and 20 men (mean age: 64.2 r years) who were selected as matched controls for breast cancer and prostate cancer respectively. These age-matched co~ 9 uls wsre selected from the subjects who attercled the hospital during the same pedod with minor su~cal ailments, but without any history of breast disease or prostate disease and without any hormonal therapy within the period of 3 months before the time of collection of I~ood. Standard questionnaires relating with clinical and epidemiological parameters as well as diet habits ware used for all patients and control subjects. Serum was separated within 6 hours of collection of blood and was stored at-20~ until the samples were analysed. Triglycerides, total cholesterol and HDL-cholesterol were estimated in an autoanalyzer by the enzymatic methods. Triglycendes and total cholesterol were measured at 500 nm by standard coupled ermjmatic wocedures ( 16, 17) . HDLcholesterol was determined by the phosphotungstic acid and magnesium chloride precipitation method. After contrifugation, the supematant which contained HDL-fraction was assayed (18) . LDL-cholest~ol was calculated from the measured concentrations of total cholesterol, HDL-cholesterol and triglycerides, according to the formula of Friedewald et al (19) . along with vegetarian (veg) and non-veg patients.
RESULTS
Amongst 25 cases of breast carcinoma, 10 patients were premenopausal while remaining 15 patients ~ po~-~-~K~0ausal. Past history of benign breast disease was found in 12% (3/25) of breast cancer patients and family history of breast cancer was present in 8~ of cases. Only I patient had histow of oral ~v e use. 60% (15/25) breast cancer patients ~ veg and rest were non-veg. 1 breast cancer patient had smoking habit and none of the patients was alcoholic. 4 patients had hypertension. Metastasis to lymph node was found in 22 cases of breast cancer.
ImmunoposiUvity to EGF-R (Fig 1) and r oncoprotein (Fig 2) ~ere in 40% (10/25) and 32%(8/ 25) cases of breast tumours respectively. Further, immuncexpression of ER (Rg 3) and PgR (Fig 4) were also observed in 36%(9/25) and 52%(13/25) of breast cancer cases respectively. Only 1 case of control ti$_~_Jes (fibroadenoma) showed immunoexpres~_' ___' on of EGF-Ro We found an association of statistically borderline significance (P=0.05) ~ lymph nodP
Statistical analysis: Fisher's exact test was employed to observe the association amongst immunomaclivity to EGF-R, c-erbB-2 orcoprotein and lymph node involvement in breast and prostate cancers. Mann-Whitney test was employed to compare the means of various serum lipid fractions between cancer patients and controls as well as positive vs. negative ~ of various receptors status limited number of subjects included in this study. involvement (metastasis) and EGF-R i r n m~i t y . But, no such association was observed with c-edoB-2 ( Table 1 ). The immunoexpressions of EGF-R, c-erbB-2, ER and PgR did not show any significant interrelationship among breast cancer, possibly due to Table 2 shows mean and standard deviation (S.D.) of different serum lipid fractions (i.e., triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol) of breast cancer patients (n=25) and control women (n=25). 
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Fig. 5. I m m u n o h i s t o c h e m i c a l e x p r e s s i o n o f E G F -R in p r o s t a t e c a n c e r ( x 400).
In prostate cancer, immunohistochemical positivity for EGF-R (Fig 5) was noticed in 30% of cases (6/20) ; while 35% (7/20) v, ere positive for cerbB-2 oncoprotein (Fig 6) . The present study could not detect immu~oeKpressk~ of ERin prostate cancer tissues; whereas, 2 cases (10%) showed positivity for PgR. In our study, interestingly, a statistically significant relatior~p (P<0.05) was observed between the irnmunoe~p,-_,~_-_-_-~ns of EGF-R and o-eta-2 among prostate cancer cases. But, no relationship was det__~'cl_ between lymph node involvement and either ofthesetwo protein-receptors (Table 1) . Further, in4 control tissues (BHP), 2 control samples showed immunq3os~ity for c-ebB-2 orcopro~n and I tissue was positive for EGF-R. Ho~=ver, no concomitant expression of these two receptors was observed in BHP. Table 3shows 
Tdglyceddes
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Prostate cancer patients (n=20) Control men (n=20) EGF-R positive cases (n=6) EGFR-R negative cases (n=14) c-erbB-2 positive cases (n=7) c-erbB-2 negative cases (n=13) Veg patients (n=13) Non-veg patients (n=7) 
DISCUSSION
The most frequently implicated receptors and growth factors in human cancers are members of the EGF-R family and their ligands. ~ receptors share a common molecular architecture as they all possess a large glycosylated extracellular ligand-binding domain and a single hydrophobic transmembrane domain as well as a cytoplasmic tyrosine kinase domain (20) . EGF-R and c-erbB-2 are the two most important members of this EGF-R family. EGF-R is a 170KD b'ansmenYo~ane glycoprotein that is expressed pdmadly on the epithelial cells of a variety of tissues. The c-erbB-2 gene is located on chromosome 17 at q21 and encodes r protein, a transmembrane receptor-like phosphoglyo~=otein of 185KD, which is closely related in stucture but is still biologically distinct from the EGF-R.
The present study revealed immunoexpression of EGF-R in 40% (10/25) while 32% (8125) immunopositivity of c-erbB-2 among breast cancer patients. ~er, concomitant pos~ity for these two proteins (EGF-R and c-eta2) was observed in 2 cases; whereas, 9 cases of breast cancer were negative for both ~ pw-oteins. The r gene has been reported to be amplified in 10-30% of most types of human adenocarcinomas, including breast cancer. Lipponen et al (21) found that 31% of patients of 10mast cancer were positive for c-erbB-2. The finclngs on immunoexpr _~__r of EGF-R and c-erbB-2 of this study are in confirmation with the report of Ratnakar et al (15) . In addition, our study noticed a correlation of border line significance between the immunopositivity of EGF-R and lymph node involvement; however, no such relationship could be established with c-erbB-2 p(otein. Ioachim et al (22) also demonstrated a significant correlation between EGF-R and o-ebB-2 i~ity with lymph rxx~e status. On the contrary, Koutseiini et al (23) observed that EGF-R status ~s not correl_=~d__ w;th lymph node involvement.
Breast cancer progms~on is ralated to a gradual loss of estrogen requirement for tumour growth. The escape from hormonal control indicates a poor prognosis, and may be associated with c-erbB-2 and/ or EGF-R over-expression which are found more frequently in primary breast tumour tissues with negative steroid hormone receptor status (24, 25) . Those tumours which are EGF-R and/or c-erbB-2 positive, may be responsive to circulating EGF and other growth factors, and do not rely upon estrogen for growth stimulation. This study has shown overexpression of ER in 32% (8/25) cases and PgR in 52%(13/25) cases of breast cancer. However, data of the present study could not establish any relationship between these two steroid hormone receptors and EGF-R or c-erbB-2 protein in breast cancer.
Several studies have supported an association betv~--~'~ breast cancer and blood lipids (6,7); alttmugh, some reports did not find such association (26, 27) . We have observed through this study that breast cancer patients had higher levels of serum triglycericles, total cholesterol and LDL-cholesterol as compared to controls. While levels of HDL-cholesterol was significantly higher in control women. Qi et al (28) and Goodwin et al (29) also reported higher triglycerides level in breast cancer patients. Takatani et al (30) suggest___~l that elevated levels of ldgyceddes have been _~' --~_ __-' -~r with Io~r conce~-~h a~Jon of sexhormone binding globulin, leading to an increased amount of free estrogen and increased breast risk. However, our observations regarding total ct-K~esterol, HDL-cholesterol and LDL-cholesterol have supported the findings of some earlier studies (5, 7, 28, 31) .
It is an interesting finding of this study that significantly higher HDL-cholesterol levels were associated with the ER-positive patients than ERnegative pa'dents with breast cancer. Over-expres__~on of ER is considered as a good prognostic marker in breast malignancy; whereas, HDL is rich in protein content, therefore, this lipoprotein may be considered as an indicator of the nutritional status of a person. Over-ex _press!__' on of ER and higher serum level of HDLcholesterol might be helpful fora better ciinical course. There is a r',ccd to elaborate the study to substar~date the relationship between ER status and HDLcholesterol in breast cancer. Ho~,=ver, no significant difference in any of serum lipid fractions was found between positive and negative sub-group of breast cancer cases for EGF-R/c-erbB-2 or PgR.
It is most striking finding of the study that no significant differences could be noticed in the levels of serum triglycerides, total cholesterol, HDLcholesterol and LDL-cholesterol in patients with prostate cancer as compared to controls. Similarly, no difference was observed in serum lipid fractions between EGF-R or c-erbB-2 positive and negative cases of prostate cancer. This phenomenon is of utmost significance due to the fact that both cancers of prostate and breast are sex-steroid hormone dependent tumours, while these tumours have distinct biological behaviours. Difference between these two cancers is also observed in immunoexpressions of various receptors in our study. The existence of ER in human prostate has long been a controversial issue. This also supports the observation of this study, as none of the cases of prostate cancer reveal positivity for ER. However, 2 cases (10%) showed immunoexpression of PgR. Our study also revealed EGF-R positivity in 30% (6/20) cases of prostate cancer. Further, 1 out of 4 BHP cases showed EGF-R positivity in the present study. Most immunohistochemical studies have shown more EGF-R expression in the benign prostatic epithelium than in prostate cancer (32, 33) . A significant positive correlation between immunoexpressions of c-erbB-2 and EGF-R among patients of prostate cancer is of utmost clinical importance as association between over-ex _pre-_~-, 3"__ _' _on of EGF-R and poor prognosis has not been demonstrated in prostate cancer. Several investigators have shown that the prognosis of prostate cancer patients with positive immunostaining for cerbB-2 protein is significantly worse than that of patients with negative staining (11, 12) .
The pathogen~s of ~ cancer is a complex process involving inter-actions of various hormone-related factors. Breast and prostate cancer have several parallels. It will be a groat value to analyse the similarities and differences as well as to evaluate different concerned factors to delineate their synergistic role in the carcinogenesis. Therefore, a comparative study on biological behaviour of carcinomas of the breast and prostate on a larger for better understanding of the pathological process. number of subjects will provide some interesting clues
